Lenz & Staehelin with Archimed on ExcellGene acquisition
Lenz & Staehelin advised private equity healthcare specialist Archimed on its acquisition of a majority stake in family-owned ExcellGene and sister company Magellan Biologics & Consulting, both active in the biologic therapeutics sector.
The deal
Pursuant to the deal, the buyer will partner with founders and managers of the selling parties in a group covering gene transfer, cell line development and cell culture-based manufacturing for high-performance production of recombinant proteins.
The Lenz & Staehelin team
Andreas Rötheli (pictured left) and Federico Trabaldo Togna (pictured right, both corporate and M&A) led the Lenz & Staehelin lineup on the matter, working alongside Ipek Yüce, Youniss Mussa, Alissa Fourati and Charles Beltjens (all corporate and M&A), Floran Ponce, Kimberly Hundt and Victoria Kinson (all tax), as well as Sevan Antreasyan, Anne-Laure Laplace and Gabriel Chaix (all IP and regulatory).
